What is HC Wainwright’s Forecast for COYA Q1 Earnings?

Coya Therapeutics, Inc. (NASDAQ:COYA) – HC Wainwright issued their Q1 2026 earnings estimates for shares of Coya Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.50) for the quarter. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.49) EPS and FY2026 earnings at ($1.93) EPS.

Several other analysts also recently issued reports on the company. Chardan Capital reiterated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Tuesday, May 13th. D. Boral Capital restated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Tuesday, April 22nd.

Coya Therapeutics Stock Performance

NASDAQ:COYA opened at $5.86 on Tuesday. The company has a market capitalization of $98.01 million, a P/E ratio of -9.02 and a beta of 0.49. The stock’s 50 day moving average price is $6.02 and its 200 day moving average price is $6.16. Coya Therapeutics has a 52 week low of $4.65 and a 52 week high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) EPS for the quarter, meeting analysts’ consensus estimates of ($0.44). The company had revenue of $257.88 million for the quarter, compared to analysts’ expectations of $2.63 million.

Institutional Investors Weigh In On Coya Therapeutics

A number of large investors have recently bought and sold shares of COYA. Newbridge Financial Services Group Inc. acquired a new position in shares of Coya Therapeutics during the fourth quarter worth approximately $401,000. Tower Research Capital LLC TRC raised its position in Coya Therapeutics by 1,005.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after purchasing an additional 4,777 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Coya Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock worth $863,000 after buying an additional 8,267 shares in the last quarter. AIGH Capital Management LLC boosted its position in Coya Therapeutics by 85.0% in the 4th quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company’s stock valued at $6,883,000 after buying an additional 551,725 shares during the last quarter. Finally, DME Capital Management LP increased its stake in shares of Coya Therapeutics by 29.2% in the 4th quarter. DME Capital Management LP now owns 1,646,440 shares of the company’s stock valued at $9,434,000 after buying an additional 372,414 shares during the period. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.